PCSK9 inhibition with alirocumab decreases plasma lipoprotein(a) concentration by a dual mechanism of action in statin‐treated patients with very high apolipoprotein(a) concentration

Abstract

<p><b>Background.</b> Inhibition of proprotein convertase subtilisin/kexin type 9 with alirocumab decreases plasma lipoprotein(a) [Lp(a)] levels. The kinetic mechanism for lowering Lp(a) by alirocumab may differ according to pre-treatment apolipoprotein(a) [apo(a)] levels.</p><p><b>Methods.</b> The effect of 12-week alirocumab (150 mg subcutaneously fortnightly) on the kinetics of apo(a) was compared in statin-treated patients with high (<i>n</i> = 10) and very high Lp(a) concentrations (<i>n</i> = 11).</p><p><b>Results.</b> In patients with high apo(a) concentrations, alirocumab lowered plasma apo(a) pool size (–17%, p < 0.01) chiefly by increasing the fractional catabolic rate (FCR) of apo(a) (+27%, p < 0.001). By contrast in patients with very high apo(a) concentrations, alirocumab significantly lowered plasma apo(a) pool size (–32%, p < 0.001) by both increasing apo(a) FCR (+30%, p < 0.001) and lowering production rate (–11%, p < 0.05).</p><p><b>Conclusions.</b> In statin-treated patients with very high apo(a) concentrations, alirocumab lowers plasma Lp(a) concentration by a dual mode of action that increases the clearance and decreases the production of Lp(a) particles.</p>